News Release Detail

July 9, 2002

Mylan Receives Approval for Nizatidine Capsules

Mylan Receives Approval for Nizatidine CapsulesPITTSBURGH, Jul 9, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Nizatidine Capsules, 150 mg and 300 mg.

Mylan Nizatidine is the generic equivalent of Reliant Pharmaceuticals' Axid® Capsules. Axid is indicated for the treatment of active duodenal ulcer and maintenance therapy for duodenal ulcer patients and also for the treatment of endoscopically diagnosed esophagitis and benign active gastric ulcer.

    The product will be shipped before the end of the week.
Mylan Laboratories Inc., is a leading pharmaceutical company that develops, manufacturers and markets generic and proprietary prescription pharmaceutical products. The company markets an extensive line of generic products through three business units, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., and UDL Laboratories, Inc. and branded products through its Bertek Pharmaceuticals Inc. subsidiary. For more information, visit www.mylan.com

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking statements regarding our anticipated financial results and estimates, business prospects and products in research and under going development, all of which involve substantial risks and uncertainties. Such risks and uncertainties are not predictable or quantifiable; consequently, should known or unknown risks or uncertainties materialize, or should our assumptions or estimates prove inaccurate, actual results could differ materially from those expressed or implied by such forward-looking statement. For further details and a discussion of such risks and uncertainties, we encourage you to read Forward-looking Statements found in our Annual Report on Form 10-K for the fiscal year ended March 31, 2002, and in our periodic reports on Forms 10-Q and 8-K (if any).

We assume no obligation to update any forward-looking statements presented here today, whether as a result of new information, future events or otherwise.

CONTACT:          Mylan Laboratories Inc., Pittsburgh                                 
                  Patricia Sunseri, 412/232-0100

URL:              http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.


Copyright (C) 2002 Business Wire.  All rights reserved.
Email Alerts
Investor FAQs
Contact Us
LinkedIn